Advertisement

Digestive Diseases and Sciences

, Volume 60, Issue 3, pp 722–733 | Cite as

Colorectal Cancer in Young Adults

  • Jennifer A. Inra
  • Sapna Syngal
REVIEW

Abstract

The incidence and mortality rates of colorectal cancer (CRC) have been decreasing in adults over 50 years of age, however, these rates have been increasing in adults under 50. The majority of CRC in young adults is sporadic, and is likely due to behavioral and environmental causes, however the exact etiology still remains unclear. The minority of CRC in this population is due to inherited CRC syndromes. Young adults with CRC are often symptomatic (abdominal pain, rectal bleeding), and diagnosis is often delayed due to reasons such as under-utilized health care services, and physicians attributing symptoms to diagnoses other than CRC. Young adults with CRC often have more aggressive tumor characteristics, but they tend to have better survival rates when compared with older adults when matched for stage. Treatment is the same for young patients with CRC, however there are issues that arise in this population that do not necessarily affect older adults, such as the negative effect of chemotherapy/radiation on fertility. It is not clear that screening individuals for CRC at ages under 50 is beneficial or cost-effective. Further studies are needed regarding this topic.

Keywords

Colorectal cancer Young adults Colorectal cancer screening Review 

Notes

Acknowledgments

The authors would like to thank Matthew Yurgelun, M.D. for thoughtful review and suggestions. Supported by NCI Grant K24 113433.

Conflict of interest

None.

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Preventive US. Services task force. Screening for colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2008;149:627–637.CrossRefGoogle Scholar
  3. 3.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Austin H, Jane Henley S, King J, Richardson LC, Eheman C. Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening. Cancer Causes Control. 2014;25:191–201.CrossRefPubMedGoogle Scholar
  5. 5.
    Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1695–1698.CrossRefPubMedGoogle Scholar
  6. 6.
    O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–872.PubMedGoogle Scholar
  7. 7.
    Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the american cancer society, the US multi-society task force on colorectal cancer, and the american college of radiology. CA Cancer J Clin. 2008;58:130–160.CrossRefPubMedGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening, incidence, and mortality—United States, 2002–2010. MMWR Morb Mortal Wkly Rep. 2011;60:884–889.Google Scholar
  9. 9.
    Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216–224.CrossRefPubMedGoogle Scholar
  11. 11.
    Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg. 2014. doi: 10.1001/jamasurg.2014.1756.
  12. 12.
    Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer. 2006;119:2657–2664.CrossRefPubMedGoogle Scholar
  13. 13.
    Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009;100:611–616.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556–565.PubMedGoogle Scholar
  15. 15.
    Guthrie JF, Lin BH, Frazao E. Role of food prepared away from home in the american diet, 1977–78 versus 1994–96: changes and consequences. J Nutr Educ Behav. 2002;34:140–150.CrossRefPubMedGoogle Scholar
  16. 16.
    Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–1687.CrossRefPubMedGoogle Scholar
  17. 17.
    Chang LC, Wu MS, Tu CH, Lee YC, Shun CT, Chiu HM. Metabolic syndrome and smoking may justify earlier colorectal cancer screening in men. Gastrointest Endosc. 2014;79:961–969.CrossRefPubMedGoogle Scholar
  18. 18.
    Hong SN, Kim JH, Choe WH, et al. Prevalence and risk of colorectal neoplasms in asymptomatic, average-risk screenees 40 to 49 years of age. Gastrointest Endosc. 2010;72:480–489.CrossRefPubMedGoogle Scholar
  19. 19.
    Nottage K, McFarlane J, Krasin MJ, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol. 2012;30:2552–2558.CrossRefPubMedGoogle Scholar
  20. 20.
    Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the late effects study group. J Clin Oncol. 2003;21:4386–4394.CrossRefPubMedGoogle Scholar
  21. 21.
    Tukenova M, Diallo I, Anderson H, et al. Second malignant neoplasms in digestive organs after childhood cancer: a cohort-nested case-control study. Int J Radiat Oncol Biol Phys. 2012;82:e383–e390.CrossRefPubMedGoogle Scholar
  22. 22.
    Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011;17:405–415.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020–1027.CrossRefPubMedGoogle Scholar
  24. 24.
    Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–1487.CrossRefPubMedGoogle Scholar
  25. 25.
    Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology. 2001;121:830–838.CrossRefPubMedGoogle Scholar
  26. 26.
    Limburg PJ, Harmsen WS, Chen HH, et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol. 2011;9:497–502.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Giraldez MD, Balaguer F, Bujanda L, et al. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res. 2010;16:5402–5413.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–932.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology. 2004;127:9–16.CrossRefPubMedGoogle Scholar
  30. 30.
    Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology. 2009;137:1883–1886.CrossRefPubMedGoogle Scholar
  31. 31.
    Jenkins MA, Croitoru ME, Monga N, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev. 2006;15:312–314.CrossRefPubMedGoogle Scholar
  32. 32.
    Genetic/Familial high-risk assessment: colorectal version 2.2014. NCCN website. http://www.nccn.org/professionals/physician_gls/PDF/genetics_colon.pdf. Updated 2014. Accessed 11.06.2014.
  33. 33.
    Children’s oncology group long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancer. Children’s Oncology Group Web site. http://www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf. Updated 2013. Accessed 18.06.2014.
  34. 34.
    Beggs AD, Latchford AR, Vasen HF, et al. Peutz–Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59:975–986.CrossRefPubMedGoogle Scholar
  35. 35.
    Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308:485–492.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    O’Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187:343–348.CrossRefPubMedGoogle Scholar
  37. 37.
    Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. 2006;107:1645–1655.CrossRefPubMedGoogle Scholar
  38. 38.
    Chiang JM, Chen MC, Changchien CR, et al. Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. Dis Colon Rectum. 2003;46:904–910.CrossRefPubMedGoogle Scholar
  39. 39.
    Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77.CrossRefPubMedGoogle Scholar
  40. 40.
    Liu B, Farrington SM, Petersen GM, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med. 1995;1:348–352.CrossRefPubMedGoogle Scholar
  41. 41.
    Lukish JR, Muro K, DeNobile J, et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg. 1998;227:51–56.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Chan TL, Yuen ST, Chung LP, et al. Frequent microsatellite instability and mismatch repair gene mutations in young chinese patients with colorectal cancer. J Natl Cancer Inst. 1999;91:1221–1226.CrossRefPubMedGoogle Scholar
  43. 43.
    Benson AB III, Bekaii-Saab T, Chan E, et al. Localized colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11:519–528.Google Scholar
  44. 44.
    Colon cancer. NCCN web site. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Updated 2014. Accessed 11.06.2014.
  45. 45.
    Rectal cancer. NCCN web site. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Updated 2014. Accessed 11.06.2014.
  46. 46.
    American Gastroenterology Association. AGA institute guidelines for colonoscopy surveillance after cancer resection: clinical decision tool. Gastroenterology. 2014;146:1413–1414.CrossRefGoogle Scholar
  47. 47.
    Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the american cancer society and the US multi-society task force on colorectal cancer. Gastroenterology. 2006;130:1865–1871.CrossRefPubMedGoogle Scholar
  48. 48.
    Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116.CrossRefPubMedGoogle Scholar
  49. 49.
    Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–1471.CrossRefPubMedGoogle Scholar
  50. 50.
    Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International multicentre pooled analysis of B2 colon cancer trials (IMPACT B2) investigators. J Clin Oncol. 1999;17:1356–1363.Google Scholar
  51. 51.
    Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999–4005.CrossRefPubMedGoogle Scholar
  52. 52.
    Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol. 1995;13:2936–2943.PubMedGoogle Scholar
  53. 53.
    O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–3388.CrossRefPubMedCentralPubMedGoogle Scholar
  54. 54.
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet. 1995;345:939–944.Google Scholar
  55. 55.
    Quah HM, Joseph R, Schrag D, et al. Young age influences treatment but not outcome of colon cancer. Ann Surg Oncol. 2007;14:2759–2765.CrossRefPubMedGoogle Scholar
  56. 56.
    Weeks JC, Catalano PJ, Cronin A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367:1616–1625.CrossRefPubMedCentralPubMedGoogle Scholar
  57. 57.
    Lee SJ, Schover LR, Partridge AH, et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–2931.CrossRefPubMedGoogle Scholar
  58. 58.
    Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv. 2007;62:58–72.CrossRefPubMedGoogle Scholar
  59. 59.
    O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28:558–562.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of GastroenterologyBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Population Sciences DivisionDana-Farber Cancer InstituteBostonUSA

Personalised recommendations